Bruker BioSciences.Bruker BioSciences first quarter sales increased 9.9% to $74.9 million, and operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. climbed 80.3% to $2.5 million. The increase in revenues was attributed to a 3.6% gain from currency effects and 6.3% organic growth. The gain in operating profit Operating profit (or loss) Revenue from a firm's regular activities less costs and expenses and before income deductions. operating profit See operating income. resuted from an improvement in gross margin by nearly two full points to 41.9% of sales. Life Science Mass Spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. revenues represented 41% of sales, X-Ray System sales System sales is a business term used in the franchising industry. Franchisors provide supplies, marketing and administration services to franchisees in return for a part of the franchisees' revenues. Some franchisors also operate some outlets directly. accounted for 29%, NBC NBC in full National Broadcasting Co. Major U.S. commercial broadcasting company. It was formed in 1926 by RCA Corp., General Electric Co. (GE), and Westinghouse and was the first U.S. company to operate a broadcast network. Detection System sales represented 5% and Aftermarket revenues accounted for 25%. Bruker BioSciences experienced strong demand from the academic market as well as nonprofit organizations, particularly in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . The strongest sales growth came from the Asian/Pacific region, particularly Japan. US and Europe both demonstrated growth, but Europe slightly stronger. Bruker Daltonics reported a 9.8% increase in sales to $42.6 million, with operating income climbing 67.3% to $3.0 million. On an organic basis, sales grew 6.3%. Life Science Mass Spectrometry Systems sales increased 5.6% to account for 70% of Daltonics sales, Substance Detection Systems sales increased 26.6% to account for 10% of Daltonics sales and Aftermarket sales accounted for 20%, up 10.8%. Bruker AXS revenues gained 10.9% to $32.5 million, or 6.4% growth organically. Operating income turned a profit of $0.8 million from a loss of $0.2 million in the previous same period. X-Ray System revenue increased 12.8% and Aftermarket sales rose 7.0%, accounting for 68% and 32% of AXS AXS Access AXS Anomalous X-Ray Scattering AXS Alpha Chi Sigma AXS Alpha X-Ray Spectrometer AXS Activex Script sales, respectively. Growth was driven by strong sales of life sciences and materials research x-ray diffraction systems and strong aftermarket sales, partially offset by reduced sales of x-ray fluorescence elemental composition systems. Due to limited visibility, the company did not provide second quarter guidance. The company remains cautious about the remaining months of 2005 due to a slowdown reported by competing companies, but reiterated its year-end revenue guidance of 10%-12% sales growth and a 3%-5% increase in operating income. Bruker BioSciences stated it does not plan any additional cost cutting measures this year.
First Quarter Ended March 31
2005 2004 %
($USD M) 1Q 1Q Chg.
Rev. 74.9 68.2 9.9%
Op. Profit 2.5 1.4 80.3%
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion